Solid Tumor Market Market Dynamics, Forecast, Analysis and Supply Demand 2015 - 2023

Solid tumors are formed due to aggregation of a group of abnormal tissues that do not comprise of any cyst or liquid areas within. Solid tumors can be of both types, i.e. benign (non-cancerous) as well as malignant (cancerous) in nature. Solid tumors majorly comprise of lymphomas, carcinomas, sarcomas and melanomas; whereas, all forms of leukemias usually do not cause solid tumor formation. The treatment of these solid tumors is a complex task and it requires coordinated actions of many healthcare professionals, such as, radiologists, surgeons, oncologists, radiation specialists, nurses and other professionals. Hence, most of the solid tumors are treated via radiotherapy, chemotherapy and/or surgery. However, at present, surgery is the most preferred choice of treatment for cancerous solid tumors. Chemotherapy is often utilized along with other modes of solid tumor treatment i.e. radiation and/or surgery. Several chemotherapeutic drugs are available along with a ripe pipeline of drugs that will soon be commercialized in the global market. Solid tumor market can be classified into five major segments, based on the site of origin, namely, prostrate cancer, ovarian cancer, bladder cancer, pancreatic cancer and other cancers.

Report Overview and TOC @ https://www.transparencymarketresearch.com/solid-tumor-market.html 

Some of the major driving factors for the growth of this market include increasing incidences of several cases of solid tumors, rising prevalence of different forms of metastatic cancers, increasing demand for highly effective chemotherapeutic agents and ripe pipeline of drugs which is available in the global market. According to World Health Organization (WHO), approximately 8.2 million people died due to different types of cancers worldwide in 2012. Among them lung, colorectal, breast and liver cancers were among the leading causes of cancer deaths. Most common forms of solid tumors include brain tumors (medulloblastoma and glioma) and neuroblastoma; other less common solid tumors include rhabdomyosarcoma and osteosarcoma.

Request brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8209

Some of the major drugs that available in the global market are Avastin (bevacizumab), Afinitor (everolimus), Jevtana (cabazitaxel), Sutent (sunitinib), Tarceva (erlotinib), Taxotere (docetaxel), Zytiga (abiraterone acetate), Carboplatin, Cisplatin, Doxorubicin, Gemcitabine and Paclitaxel among others. Also, major promising drugs that are in different stages of clinical trials include Abraxane (albumin-bound paclitaxel), AMG 386 (trebananib), Votrient (pazopanib) and Xtandi (enzalutamide) among others. These drugs will soon be commercialized in the global market, which will further boost this market in future.

For Specific and Customized requirements@ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=8209

Geographically, North America holds the leading position in solid tumor market followed by Europe. Major factors responsible for their dominance in this market include high incidence rate of various solid tumor cases along with very well developed healthcare infrastructure of these regions. These regions also comprise of high geriatric population, which contribute heavily towards the solid tumor patient population in the region. However, Asia Pacific is considered to be the most lucrative market for solid tumor market due to recent advancements in healthcare infrastructure and growing medical tourism in these regions. The region also accounts for high cancer patient population and increasing awareness and affordability of the people of this region will contribute heavily towards the future growth of this market in the region.

Pre Book full report@ https://www.transparencymarketresearch.com/solid-tumor-market.html?secure=NTIxNS41&type=PB

Some of the major players operating in this market are AstraZeneca plc, Abbott Laboratories, Inc., Amgen, Inc., Biogen Idec, Inc., Boehringer Ingelheim GmbH, Baxter International, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Johnson & Johnson, GlaxoSmithKline plc, Kyowa Hakko Kirin Co., Ltd., and Sanofi among others.

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Transparency Market Research

State Tower
90 State Street,
Suite 700,
Albany NY - 12207
United States

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

This release was published on openPR.